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Abstract: Background: New sensor technologies in wearables and other consumer health devices
open up promising opportunities to collect real-world data. As cardiovascular diseases remain the
number one reason for disease and mortality worldwide, cardiology offers potent monitoring use
cases with patients in their out-of-hospital daily routines. Therefore, the aim of this systematic review
is to investigate the status quo of studies monitoring patients with cardiovascular risks and patients
suffering from cardiovascular diseases in a telemedical setting using not only a smartphone-based
app, but also consumer health devices such as wearables and other sensor-based devices. Methods: A
literature search was conducted across five databases, and the results were examined according to the
study protocols, technical approaches, and qualitative and quantitative parameters measured. Results:
Out of 166 articles, 8 studies were included in this systematic review; these cover interventional and
observational monitoring approaches in the area of cardiovascular diseases, heart failure, and atrial
fibrillation using various app, wearable, and health device combinations. Conclusions: Depending on
the researcher’s motivation, a fusion of apps, patient-reported outcome measures, and non-invasive
sensors can be orchestrated in a meaningful way, adding major contributions to monitoring concepts
for both individual patients and larger cohorts.
Keywords: telemonitoring; telemedicine; telecardiology; cardiology; wearable; sensors; consumer
health devices; cardiovascular disease; heart failure; atrial fibrillation
1. Introduction
Within the last decade, advances in sensor technology have made a large number
of wearables and other consumer health devices ready for the market. Both leading
technology companies and specialized manufacturers have acknowledged a need for
affordable and accessible integrated sensor technologies for fitness and health; they are
serving this trend with significant investments in the emerging market [1]. One result
is a progressive penetration of these technologies into a large proportion of the general
public, given that consumer health devices allow individuals to measure cardiac vital signs
while working out, or to self-monitor their own health status, potentially improving an
individual’s health behavior [2]. As these technologies become more widespread and
sophisticated, there are many potential applications and use cases; several of these involve
monitoring individual patients’ and entire cohorts’ physiology in the context of everyday
life. This potential has been recognized by both researchers and health care professionals,
as remote patient monitoring opens up new sustainable ways to support and care for
patients in their homes [3–5]. In particular, the field of cardiology can be considered
one of the most important fields of application, as integrated sensor technologies allow
a variety of use cases, following up with a patient’s cardiovascular health status under
real-world conditions while avoiding clinical biases such as white coat hypertension [6–8].
On the other hand, cardiovascular diseases are the leading cause of death in the European
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countries and, therefore, avoiding these has a huge impact on public health and the health
system. For example, heart failure affects approximately 26 million people worldwide [9].
Once hospitalized, up to 25% of heart failure patients are readmitted within 30 days [10,11].
Thus, recognizing the worsening of heart failure and avoiding hospital admissions is a key
quality metric for managing heart failure patients.
This also influenced the researchers of the Use Case Cardiology (UCC) of the HiGH-
med [12] consortium when planning the integration of both institutional and cross-sectional
heart failure (HF)-related health care data in 2017. As part of an affiliated telemonitoring (TM)
study, the application of wearables in the follow-up care of HF patients is planned. The aim is
to support patients and their physicians in the disease management of HF while simultane-
ously aggregating health data from the “black box” home setting by equipping patients with
wearables, complementary devices, and patient-reported outcome measures (PROMs). The
aggregated data will then be transferred into a medical data integration center and merged
with the hospitals’ electronic health records (EHRs) to create a longitudinal dataset of HF
patients. Therefore, it is the consortium’s premise to develop and deploy low-threshold
state-of-the-art solutions. In doing so, our aim is to passively observe the patients’ disease
progression retrospectively, without requiring any additional intervention. Thus, our study
focuses on the latest consumer technologies that are suitable for everyday use.
In order to obtain an overview of recent research- and technology-related develop-
ments in the field, the main objective of this systematic review is to investigate the status
quo of studies monitoring patients with cardiovascular risks and patients suffering from
cardiovascular diseases in a telemedical setting, using not only a smartphone-based app,
but also consumer health devices such as wearables and other sensor-based devices. With
this novel approach, we aim to provide a holistic perspective on telemonitoring as we take
both the general organizational and technical context as well as qualitative and quantitative
aspects into consideration.
2. Materials and Methods
We performed a systematic review in order to identify published articles regarding
telecardiological studies using consumer health devices to monitor patient’s’ health sta-
tus reported via a mobile app. We identified and evaluated the available literature in
accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines [13] though no registration of the protocol was performed.
2.1. Search Strategy
We conducted this comprehensive and systematic search of five databases for literature
published between 1 January 2001 and 31 March 2021. We identified relevant English-
language publications searching PubMed, Web of Science, CINAHL, Cochrane Library, and
Scopus. The mandatory keywords (“telemedicine” OR (“telecardiology” AND “cardiology”
OR “cardiovascular disease”) AND “app” OR “mobile application”) were used for the
search. We provide detailed queries in Table 1.
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Table 1. Our search queries as we executed them per database.
Database Query
PubMed
((telemedicine OR telecardiology [Title/Abstract]) AND (cardiology OR “cardiovascular disease”
[Title/Abstract]) AND (app OR mobile application [Title/Abstract])) AND ((“2001/01/01”
[Date—Publication]: “2021/03/31” [Date—Publication]))
CINAHL
((telemedicine OR telecardiology [Title/Abstract]) AND (cardiology OR “cardiovascular disease”
[Title/Abstract]) AND (app OR mobile application [Title/Abstract])) AND ((“2001/01/01”
[Date—Publication]: “2021/03/31” [Date—Publication]))
Cochrane (telemedicine OR telecardiology):ti,ab AND (cardiology OR “cardiovascular disease”):ti,ab AND (app ORmobile application):ti,ab” with Cochrane Library publication date between Jan 2001 and Mar 2021
Web of Science
(AB = ((telemedicine OR telecardiology) AND (cardiology OR “cardiovascular disease”) AND (app OR mobile
application))) OR (TI = ((telemedicine OR telecardiology) AND (cardiology OR “cardiovascular disease”)
AND (app OR mobile application))) (Search period was set via the UI of Web of Science.)
SCOPUS
((ABS (telemedicine OR telecardiology) AND ABS (cardiology OR “cardiovascular disease”) AND ABS (app
OR mobile AND application))) OR ((TITLE (telemedicine OR telecardiology) AND TITLE (cardiology OR
“cardiovascular disease”) AND TITLE (app OR mobile AND application))) AND (LIMIT-TO (SRCTYPE, “j”)
OR LIMIT-TO (SRCTYPE, “p”)) (Search period was set via the UI of SCOPUS.)
Proper names are shown in italics.
2.2. Inclusion and Exclusion Criteria
We intended to include articles matching the following criteria: (1) primary studies
dealing with (2) telemedical concepts in (3) cardiovascular disease monitoring that used
(4) consumer health devices such as wearables (5) or other noninvasive sensors to (6) track
patients’ health data (7) with a smartphone app as a central user interface. Studies not
considering both wearable- and sensor-generated data were excluded.
2.3. Selection and Data Extraction
We managed the retrieved articles of each search in the aforementioned databases with
Citavi 5 (Swiss Academic Software GmbH Citavi 5 Version 5.7.1.0., Wädenswil, Switzer-
land). First, we removed duplicates; then, we identified relevant articles by screening all
keywords, titles, and abstracts based on our selection criteria. We excluded all records that
did not clearly meet the eligibility criteria. Subsequently, one experienced expert in the
field of medical informatics assessed all potentially relevant and freely available full-text
publications regarding the inclusion and exclusion criteria. In case of ambiguity, the articles
were discussed with a second expert in the domain to decide about inclusion or exclusion.
While we conducted the full-text review, we identified potentially relevant references in
the first-level results based on the context.
2.4. Comparison Criteria
In order to compare the studies, we determined various comparison criteria and
divided them into the three groups: (1) study protocol, (2) technical parameters, and
(3) qualitative and quantitative parameters.
2.4.1. Study Protocol
This group includes the framework conditions of the publications, giving an overview
of the relevant studies. As this review focuses on cardiological diseases, the disease-related
use cases form an important criterion together with both sample sizes and study cohort
sizes, study types, and the minimum participation duration. In addition, the country in
which the study was conducted, as well as the application area distinguishing between
local (e.g., Munich), regional (e.g., Bavaria), or national (e.g., Germany), were selected.
2.4.2. Technical Parameters
Consisting of whether study staff monitored patients by including intervention—i.e.,
actively intervening by adjusting a participant’s treatment/therapy plan (e.g., due to
changing measures or vital signs)—or without intervention—i.e., as a passive, observing
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character. Additionally, the platforms on which the patients’ apps were offered were
included. The third and fourth technical criteria include the applied wearables and other
non-wearable consumer health devices connected to the patients’ apps.
2.4.3. Qualitative and Quantitative Parameters
Following the group of technical parameters, this group focuses on parameters pro-
vided by (1) the patients, (2) measured via a wearable or other consumer health device,
and (3) data collected in a hospital setting by a physician, including examinations and
surveys. We further divided patient-reported data into patient-reported outcome measures
(PROMs) and patient-generated health data (PGHD). PROMs, following the definition of
Weldring et al., describe tools or instruments (e.g., standardized questionnaires) developed
to ensure a valid and reliable measurement of patient-reported outcomes [14]. Accordingly,
these can further be subdivided into the PROMs that (a) measure functional status, or
capture (b) health-related quality of life, (c) symptoms and symptom burden, (d) personal
experience of care, and (e) health-related behaviors such as anxiety and depression, as well
as PROMs that cannot be assigned to any of the above-mentioned groups because they
are, for example, non-disjunct, summarized into (f) others. While, according to Sharpio
et al., patient-generated health data (PGHD) are defined as ”health-related data including
health history, symptoms, biometric data, treatment history, lifestyle choices, and other
information created, recorded, gathered or inferred by or from a patient”‚ in this review we
focus on patient data documented via an app [15]. Finally, the specific vital signs provided
by wearables and other consumer health devices were also included as a criterion, while the
frequency by which device-tracked parameters were captured was also taken into account.
3. Results
We identified 166 articles in our initial search (see Supplementary Materials Table S1:
Databases export). After we removed duplicates, a total of 157 articles were included for
the title and abstract screening process. Among these, 30 articles seemed relevant, and we
performed a full-text review/evaluation, resulting in a total of 7 articles being eligible and
included in the study (see Supplementary Materials Table S2: Articles excluded) [16–22]. After
we did a backward reference screening, we included one additional article [23]. Finally, eight
articles were included in this systematic review. The detailed selection process is illustrated as
a PRISMA flow diagram in Figure 1.
The included articles describe studies with several different types of study design, such as
proof-of-concept studies (2 of 8; 25.0%) [19,22], randomized controlled trials (2 of 8; 25.0%) [20,23],
cluster randomized trials (1 of 8; 12.5%), longitudinal cohort studies (1 of 8; 12.5%) [16], pilot
studies (1 of 8; 12.5%) [21], and screening studies (1 of 8; 12.5%) [17]. These studies were
conducted in four different countries: three in the United States (37.5%) [18,19,21], two in
China (25.0%) [16,17], two in Germany (25.0%) [22,23], and one in Canada (12.5%) [20]. Four
studies were enrolled on national (50.0%) [16,17,19,23] and four on local (50.0%) [18,20–22]
levels, while none of the included studies were conducted at the regional level. In terms of
the use cases, heart failure was represented in three (37.5%) [20,22,23], cardiovascular disease
in three (37.5%) [18,19,21], and atrial fibrillation in two studies (25.0%) [16,17]. The smallest
study cohort comprised 10 participants. The largest study included 246,541 participants. The
minimum participation duration of all eight studies ranged from 14 days to 393 days. We
provide an overview of the results in Table 2.
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With respect to the technical characteristics of the included studies, we identified
six studies following an interventional monitoring approach (75.0%) [16,17,20–23], while
two studies used the applied app and technology to log patients’ health status for further
research (25.0%) [18,19]. The operating systems for the patient apps included Google
Android and Apple iOS; the latter was used as a platform for conducting two studies
(25.0%) [18,22]: one study was carried out using multiple platforms (12.5%) [19], and one
relied on the use of an Android-based app (12.5%) [17]. The remaining four articles (50.0%)
provided no further information about the platform(s) used [16,20,21,23]. When it comes to
the wearables used, two articles stated the use of smartwatches from Apple (25.0%) [18,22],
one article reported the use of a Fitbit wearable (12.5%) [21], one study relied on the use
of a Withings smartwatch and Withings fitness tracker (12.5%) [19], while two articles
reported the use of the Honor Band 4, the Honor Watch, and the Huawei Watch GT
(25.0%) [16,17]. Two study protocols did not plan the use of any wearables (25.0%) [20,23].
Furthermore, we analyzed whether the participants were provided with other consumer
health devices connected to the patients’ apps. We found that five study protocols included
different types of Bluetooth blood pressure monitors (62.5%) [18–21], four involved the
use of Bluetooth scales (50.0%) [19–21,23], and one study each included the use of a
glucometer (12.5%) [21], a sleep tracking system (12.5%) [19], an electrocardiography
device (12.5%) [23] and a pulse oximeter (12.5%) [23]. Some studies used a combination of
several of the aforementioned devices. Three studies did not use additional devices aside
from the wearables (37.5%) [16,17,22]. We provide an overview of the results in Table 3.
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1 BP: blood pressure; 2 SpO2: oxygen saturation.
Based on previously defined groups of PROMs, we could categorize two PROMs
as outcomes measuring functional statuses (2 of 17; 11.76%) [18,23], five as describing
health-related quality of life (29.41%) [20,22,23], three for symptoms and symptom burden
(17.65%) [16,20], one for personal experience of care (5.88%) [20], four for health-related
behaviors such as anxiety and depression (23.53%) [18,19,22], and two non-disjunct PROMs
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(11.76%) [18,22]. The exact allocation of the PROMs can be found in the (Supplementary
Materials Table S3: Categorization PROMs).
In Table 4, we provide an overview of the quantitative and qualitative parameters
described within the reviewed studies. Overall, 17 PROMs could be identified, with two
studies using one PROM (25.0%) [18,21], five studies using two or more types of PROMs
(62.5%) [16,18,20,23], and no PROMs reported in one study (12.5%) [17].
Table 4. Overview of the studies included in the systematic review, with a focus on the qualitative and quantitative parameters.
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Table 4. Cont.
Ref. PROM PGHD Clinical Parametersand Scales
Self-Tracked
Follow-Up Parameters Frequency
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1 HAS-BLED: hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio,
elderly, drugs/alcohol concomitantly score.
When it comes to PGHD, five studies (62.5%) [16–18,21,22] collected various parameters,
while three studies did not foresee the documentation of any additional data by the patient
(37.5%) [19,20,23]. These five studies took into account a variety of self-documented lifestyle
factors, such as diet (2 of 8; 25,0%) [16,21], smoking behavior (2 of 8; 25.0%) [18,21], and alcohol
use (1 of 8; 12.5%) [18]. Furthermore, therapy compliance factors such as medication adherence
(6 of 8; 75.0%) [16–18,21,22] were documented, while unspecified health surveys (1 of 8;
12.5%) [18], self-reported risk factors (1 of 8; 12.5%) [18], information about cardiovascular
disease history (1 of 8; 12.5%) [18], sociodemographic data (1 of 8; 12.5%) [18], atrial-fibrillation-
related hospital visits (1 of 8; 12.5%) [17], and hospitalizations (1 of 8; 12.5%) [17] were also
requested to be entered into the patients’ app or paper-based questionnaire. One study asked
the patients to enter their blood pressure and weight manually into the app (12.5%) [22], using
non-connected conventional devices. In addition to the aforementioned patient-reported data,
three studies reported the assessment of laboratory parameters at the beginning and in the
course of the study (37.5%) [16,20,23]. One further study used a clinical questionnaire for
the collection of data by clinical staff (12.5%) [17]. One study conducted a six-minute walk
test and an ECG examination by study personnel (12.5%) [22]. Based on the wearables and
devices to be found in Table 3, a wide range of self-tracked parameters could be identified,
including seven studies measuring the patients’ heart rate (87.5%) [16–20,22,23], six studies
measuring the patients’ blood pressure (75.0%) [16,18–21,23], four studies asking the patients
to track their weight (50.0%) [20,21,23], and two using the devices to track the daily steps or
mean daily steps (25.0%) [19,21]. Finally, the device-based self-tracking of a six-minute walk
test (6MWT) [22], no further described physical activity [19], and the measurement of blood
glucose [21], pulse wave velocity (PWV) [19], sleep duration [19], and oxygen saturation
(SpO2) [23] were each performed in one study (12.5%).
Werhahn et al. equipped patients with the Apple Watches to measure their heart
rate. They used built-in pedometer functions of both smartphones and Apple Watches to
capture daily steps, calculated as an arithmetic mean of 14 days. During three planned
study site visits, the device-based 6MWT was validated by simultaneously carrying out a
regular 6MWT [22]. Wenger et al. report that their trial participants measured their blood
glucose levels daily using a glucometer, as well as their daily steps using the Fitbit’s built-in
pedometer; moreover, they collected participants’ blood pressure and bodyweight once a
week on the same day using a Bluetooth BP monitor and weight scale [21]. Seto et al. did not
use any wearables, but did use Bluetooth BP monitors and weight scales to measure heart
rate, blood pressure, and bodyweight daily [20]. Modena et al. included patients already
owning a Withings fitness tracker or Withings Watch and BP monitor, weight scale, or
sleep-tracking system to track their participants’ pulse wave velocity, blood pressure, heart
rate, and bodyweight at least two days a week, while the participants’ physical activity
levels were captured using the built-in activity trackers on the participants’ smartphones.
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Additionally, Modena et al. described measuring the participants’ sleep duration via a
Withings smartwatch or a sleep-tracking system if available [19]. McManus et al. report
that they equipped a subpopulation of their study cohort with an Apple Watch and an
additional Bluetooth BP cuff to log their blood pressure weekly as well as their daily
measured heart rate [18]. Guo and Wang et al. included participants owning a Huawei
Watch GT, Honor Watch, or Honor Band 4 to frequently capture their heart rate every
10 min [17]. Guo and Lane et al. used the same selection of devices to capture both heart rate
and blood pressure, but did not provide further information about the frequency [16]. No
other consumer health devices were used in either setting described by Guo et al. [16,17].
In contrast, Koehler et al. outline the application of only non-wearable-based sensors,
including ECG monitors, BP measuring devices, weighing scales, and SpO2 sensors; these
four devices were used to track the participants heart rate, blood pressure, weight, and
capillary oxygen saturation daily [23].
4. Discussion
This systematic review summarizes the findings of studies using a patient app as an
interface to document not only different sensor-based vital signs, but also self-tracked and
self-documented real-world health data, for the purpose of telemonitoring in cardiology
and observational research, including cardiological telemedicine data. The results suggest
that different types of commercially available wearables and other consumer health devices
can be implemented in a meaningful way in order to gain major insights into health
behaviors and the course of diseases in different cardiological patient cohorts.
The comparison shows that although the studies’ primary focuses were different,
there are many similarities, suggesting that the symbiosis of these new technologies in a
cardiological context seems to be of interest to researchers worldwide. To achieve their
respective objectives, all studies relied on a combination of apps and non-invasive devices.
While the interventional studies’ approach was to monitor the daily management of disease
progression or to provide active support, preventing deterioration when serious symptoms
occurred, the observational programs aimed to provide further real-world health data for
medical research, improving therapies and treatments in the long term.
Furthermore, the comparison shows that the choice of non-invasive devices is crucial
when it comes to monitoring either high-frequency data or snapshots of a patient’s health
status. This also depends on the scientific question or the context of treatment. In the
studies reviewed, sensor- and app-based monitoring was implemented on the basis of
various cardiological use cases, while some had intersections when it came to the PROMs
or self-tracked follow up parameters collected. As vital signs such as heart rate and
blood pressure or weight were taken into account by almost all of the studies reviewed,
it can be assumed that these turn out to be key physiological signals to be monitored,
providing initial insights into a patient’s general condition. However, this is countered by
the fact that the accuracy of commercial wrist-worn devices is subject to ongoing scientific
debate [25–27]. From a monitoring point of view, wearables have the advantage that they
can provide high-frequency streaming data while worn. Although the market for consumer
health devices is rapidly evolving, the types of sensors used in commercially available
wearables are still limited, e.g., blood pressure, heart rate, SpO2, electrocardiogram, or
photoplethysmography; thus, the need for both further developments in current sensors
(e.g., wrist-worn ECG with more leads) and new sensor technologies was also recognized in
the studies examined. This is why in some studies additional consumer health devices were
applied to add follow-up parameters that generally cannot yet be captured by wearables or
cannot be captured with sufficient quality. Adding to this, the review found that frequent
surveys of standardized PROMs via a patient app seem to be another meaningful way to
assess various aspects of a patient’s health status at home by adding further assessment
criteria. Moreover, the digitization of PROMs seems to be a meaningful step towards a
more patient-centered treatment [28,29]. While, from our point of view, for purposes of
analysis, the use of structured data acquisition is to be preferred, there is much to be said
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for expanding the data basis through simple surveys, such as confirmation of medication
intake or documentation of dietary behavior, as practiced in some of the programs.
Werhahn et al.’s study required patients to manually enter self-measured body weight
as well as other parameters into the app without fully exploiting the possibilities of au-
tomatically transferring measurements by using existing interfaces such as Bluetooth. In
contrast are Seto et al.’s, Moderna et al.’s, and Koehler et al.’s approaches to reduce the
hurdle for regular data transfers to the app by equipping patients with Bluetooth scales.
Thus, the manual entry of patients’ medical history by the patients themselves, as described
by McManus et al., has potential for improvement, as this data could already be stored in
the patient’s EHR or personal health record (PHR). Seto et al. describe a practical example,
as they explicitly mention the import of laboratory parameters—e.g., brain natriuretic
peptide (BNP) levels—from their hospital’s EHRs. Furthermore, Koehler et al. also took
the BNP level into account, while Guo et al. took hemoglobin, liver, and renal function
in both screened studies into consideration for the prediction of deterioration of the state
of health. This review did not investigate whether or how laboratory parameters were
transferred to the app but, again, it seems reasonable to do so by integrating the EHRs.
Among all of the studies considered, Wenger et al. were the only team to use a point-of-care
test, as synchronized glucometers to measure patients’ blood glucose were handed to the
participants. This demonstrates that further laboratory parameters, which can currently
only be measured by health care professionals, could in the future also be measured in
the home setting. This would add a wider range of parameters to be monitored. The
general advantages of mHealth technologies consist not only of bridging time and distance,
but also offer the potential to avoid resource-intensive on-site monitoring. As soon as
more over-the-counter sensors for measuring laboratory parameters reach market maturity,
further scientific and clinical value could be gained from their integration in monitoring
concepts. However, this is yet to be evaluated in further studies.
Finally, it is important to consider the platforms used, as the review revealed that only
Modena et al. took a cross-platform approach integrating real-world health data from both
Android and iOS devices. In the other studies, patients were provided with a compatible
smartphone, or were only eligible for study participation if they already owned a suitable
device. Consequently, this automatically leads to the exclusion of potential patients with
unsupported device combinations. When considering a multiplatform approach, the
corresponding effort and associated resource consumption must be taken into account.
While a less complex single-platform approach allows the full exploitation of features of
wearables or other devices via native interfaces, a comprehensive and elaborate integration
into a multiplatform application might be associated with limited access to all device
features [30]. Koehler et al., for example, integrated various consumer health devices from
different manufacturers, although the underlying platform was unknown to the authors.
In summary, although consumer health devices or wearables remain evolving tech-
nologies, they are already able to offer a meaningful contribution in providing a more
holistic insight into cardiological patients’ health status and behavior, while at the same
time bridging the distance between patient and doctor.
4.1. Limitations
The results suggest that the search terms used were appropriate for the research
question, but some limitations of our study should still be considered. For instance, our
keywords telemedicine or telecardiology could limit the choice to studies that focused on
interventional approaches, while observational studies are left out. To weaken the impact,
we added the keyword mHealth to our queries. This did not provide more results, and was
therefore dismissed. Furthermore, as the title/abstract filter was not applied constantly for
the PubMed query, this results in a slightly larger pool of findings, which had a positive
impact on the scope of our results.
In addition to the selected search terms, the challenge was to create a category
scheme in which all included studies could be meaningfully presented to provide a holis-
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tic overview without excluding relevant factors. Therefore, the scheme was limited to
categories that are relevant from the authors’ point of view. However, all information
can be found in a table in the Supplementary Materials. The separation between PGHD,
PROMs, and clinical parameters was also discussed and assessed in detail between the
authors to accomplish it as distinctly as possible; thus, we cannot ensure that everybody
would evaluate this in the same manner. Although prominent studies such as the Apple
Heart Study [5,31] were not included in the literature review, we assume that our analysis
covered studies in the clinical context of telecardiology. However, this indicates that there
may be other studies in the field that we did not include.
4.2. Outlook
In the context of this review, we did not address the algorithms used—for example,
by Guo et al. and Seto et al. to predict AF and decompensation in HF, respectively.
Although there are already internationally agreed treatment standards, there is still a
lack of transparent and uniform diagnostic algorithms, as these are the subject of current
research. It could be of interest to investigate which cardiological therapy guidelines or
standards have been used to derive rules for algorithms, and what is the status quo in
cardiologic algorithm research. Thinking beyond study situations, the possibilities of
regular patients contributing their self-tracked health data into their EHRs are also of
interest. In addition, as we advocate the establishment of platforms through which users
can donate their wearable data for public research purposes without being tied to a specific
purpose, corresponding concepts could be of interest for further research.
In future studies, it seems appropriate to replace the manual documentation of sensory
data (e.g., weight by integrating consumer health Bluetooth scales). Given this, suitable solu-
tions satisfying regulatory, technical, and medical requirements will be sought. As a second
improvement, the adaption of further or different questionnaires should be investigated.
5. Conclusions
In this systematic review, we evaluated different approaches conducted by various
researchers in the field of cardiological patient monitoring, which applied an integrated
combination of app-based surveys, wearables, and other consumer health devices. Our
review shows that, depending on the researcher’s motivation, a fusion of apps, PROMs, and
non-invasive sensors can be orchestrated in a meaningful way, adding major contributions to
monitoring concepts for both individual patients and larger cohorts. We suggest that different
combinations of device-based vital-sign monitoring combined with patient-reported outcomes
and the documentation of lifestyle factors can contribute further insights into patients’ disease
progression, therapy compliance, and general health behavior patterns. In the medium-to-
long term, disease prevention will most likely depend on consumer-health-device-based
cardiovascular risk monitoring as a tool to follow patients up.
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